Format

Send to

Choose Destination
See comment in PubMed Commons below
Cancer Treat Rev. 2013 Apr;39(2):136-41. doi: 10.1016/j.ctrv.2012.06.003. Epub 2012 Jul 15.

Finding the right dose of fulvestrant in breast cancer.

Author information

  • 1Medical Oncology Department, Centro Integral Oncológico Clara Campal, Madrid, Spain. lauraestevez@hospitaldemadrid.com

Abstract

Fulvestrant is a selective estrogen receptor downregulator, behaving as a complete antagonist. It was initially approved, at a dose of 250 mg, to treat hormone dependant breast cancer in second line setting. However, a series of pharmacological and pre-clinical studies have suggested that a higher dose of 500 mg may be more effective. The present work summarizes and discusses clinical trials that have aimed to test the benefits of administering fulvestrant at a higher dose. The data support the use of a higher, and more possibly, effective dose of the agent.

PMID:
22795960
DOI:
10.1016/j.ctrv.2012.06.003
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center